LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 345

Search options

  1. Article ; Online: The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.

    Li, Si-Min / Zhu, Feng-Cai

    The Lancet. Infectious diseases

    2024  

    Language English
    Publishing date 2024-03-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(24)00157-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?

    Jin, Pengfei / Zhu, Fengcai

    The Lancet regional health. Europe

    2023  Volume 28, Page(s) 100623

    Language English
    Publishing date 2023-03-31
    Publishing country England
    Document type Journal Article
    ISSN 2666-7762
    ISSN (online) 2666-7762
    DOI 10.1016/j.lanepe.2023.100623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2.

    Li, Jing-Xin / Zhu, Feng-Cai

    The Lancet. Infectious diseases

    2022  Volume 22, Issue 7, Page(s) 916–917

    MeSH term(s) COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Neutralization Tests ; Reinfection/prevention & control ; SARS-CoV-2/genetics ; Vaccines, Subunit
    Chemical Substances COVID-19 Vaccines ; Vaccines, Subunit
    Language English
    Publishing date 2022-04-18
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(22)00162-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Challenges of COVID-19 vaccination in patients with cancer

    Jia Siyue / Zhu Wenbo / Jiang Hudachuan / Zhu Fengcai

    National Science Open, Vol

    2022  Volume 1

    Abstract: Patients with cancer are at increased risk of SARA-CoV-2 infection or developing severe COVID-19 cases due to malignancy or immunosuppressive therapy, but they are generally excluded from the target population for COVID-19 vaccination. In general, ... ...

    Abstract Patients with cancer are at increased risk of SARA-CoV-2 infection or developing severe COVID-19 cases due to malignancy or immunosuppressive therapy, but they are generally excluded from the target population for COVID-19 vaccination. In general, inactivated vaccines are safe and immunogenic for patients with cancer, but live attenuated vaccines are not recommended. The study suggested that the safety of the mRNA COVID-19 vaccine in patients with cancer is similar to that in healthy people, but immunogenicity is slightly weaker, and a booster dose may be needed. This paper aims to summarize the results of COVID-19 vaccine clinical studies conducted in patients with cancer worldwide and the relevant guidelines released by authorities, so as to provide evidence for promoting COVID-19 vaccination for patients with cancer.
    Keywords COVID-19 ; vaccine ; clinical trial ; patients with cancer ; Science ; Q ; Engineering (General). Civil engineering (General) ; TA1-2040
    Subject code 610
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher Science Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: A Public Health Perspective on Influenza Status in the Context of COVID-19 Pandemic, 2019-2020.

    Huo, Xiang / Zhu, Fengcai

    China CDC weekly

    2021  Volume 2, Issue 44, Page(s) 870–872

    Language English
    Publishing date 2021-09-30
    Publishing country China
    Document type Journal Article
    ISSN 2096-7071
    ISSN (online) 2096-7071
    DOI 10.46234/ccdcw2020.231
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease.

    Gao, Xing-Su / Zhu, Feng-Cai

    The Lancet. Rheumatology

    2021  Volume 4, Issue 2, Page(s) e77–e78

    Language English
    Publishing date 2021-12-03
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(21)00392-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.

    Li, Jing-Xin / Zhu, Feng-Cai

    Lancet (London, England)

    2021  Volume 398, Issue 10317, Page(s) 2134–2135

    MeSH term(s) Antibodies, Neutralizing ; COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines, Inactivated
    Chemical Substances Antibodies, Neutralizing ; COVID-19 Vaccines ; Vaccines, Inactivated
    Language English
    Publishing date 2021-11-11
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(21)02014-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Adjuvantation helps to optimise COVID-19 vaccine candidate.

    Li, Jing-Xin / Zhu, Feng-Cai

    The Lancet. Infectious diseases

    2021  Volume 21, Issue 7, Page(s) 891–893

    MeSH term(s) Adjuvants, Immunologic ; COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2
    Chemical Substances Adjuvants, Immunologic ; COVID-19 Vaccines
    Language English
    Publishing date 2021-03-08
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(21)00094-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Influenza virus subtype/lineage-specific seasonal patterns and age-related infection risk, in Eastern China.

    Huo, Xiang / Fu, Junjie / Dai, Qigang / Zhu, Fengcai

    Journal of infection in developing countries

    2022  Volume 16, Issue 12, Page(s) 1928–1932

    Abstract: Introduction: Differences in seasonal pattern and age-related infection risk have been reported between Influenza type A and B, but have not been elaborated at subtype/lineage level.: Methodology: All laboratory-confirmed influenza cases reported in ... ...

    Abstract Introduction: Differences in seasonal pattern and age-related infection risk have been reported between Influenza type A and B, but have not been elaborated at subtype/lineage level.
    Methodology: All laboratory-confirmed influenza cases reported in the influenza surveillance system of Jiangsu Province, China from January 2011 to August 2019 were analyzed. Influenza seasonality was characterized using the Seasonal Decomposition method. Binary and multinomial logistic regressions were employed to calculate the odds ratios of influenza subtypes/lineages in relation to age.
    Results: A total of 28,772 confirmed influenza cases were included. Among them, a majority (64.1%) were influenza A infections. One annual peak was observed for A (H1N1) pdm and B-Yamagata in winter months, and for B-Victoria in spring months, while biannual peaks were observed for A (H3N2) in winter and summer months. Using all ages as the reference, children younger than 5 years and adults of 25-59 years were more likely to infect with A (H1N1) pdm. Older children aged 5-14 years had significantly higher odds of infection with influenza B of both lineages, while individuals aged 15-24 years had higher odds for A (H3N2) and B-Victoria. The elderly (60 years or older) were prone to be infected with A (H3N2) and B-Yamagata. For a specific age group, their likelihood of getting infected with an influenza subtype or lineage was related to the co-circulating influenza subtype or lineage.
    Conclusions: Influenza viruses have divergent seasonal peak times and age-related infection risk at subtype/lineage level.
    MeSH term(s) Adult ; Child ; Aged ; Humans ; Adolescent ; Influenza, Human/epidemiology ; Seasons ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H3N2 Subtype ; China/epidemiology ; Disease Susceptibility ; Influenza Vaccines
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2022-12-31
    Publishing country Italy
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2394024-4
    ISSN 1972-2680 ; 2036-6590
    ISSN (online) 1972-2680
    ISSN 2036-6590
    DOI 10.3855/jidc.14887
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Advances in the progress of monoclonal antibodies for rabies.

    Fan, Linlin / Zhang, Li / Li, Jingxin / Zhu, Fengcai

    Human vaccines & immunotherapeutics

    2022  Volume 18, Issue 1, Page(s) 2026713

    Abstract: Rabies is a highly fatal zoonotic disease caused by the rabies virus invading the central nervous system. When suspected of exposure to the rabies virus, post-exposure prophylaxis should be administered as soon as possible. Monoclonal antibodies (mAbs) ... ...

    Abstract Rabies is a highly fatal zoonotic disease caused by the rabies virus invading the central nervous system. When suspected of exposure to the rabies virus, post-exposure prophylaxis should be administered as soon as possible. Monoclonal antibodies (mAbs) neutralizing the rabies virus could be better in human rabies post-exposure prophylaxis than equine or human rabies immune globulin in terms of supply, cost, and efficacy. This article reviews anti-rabies mAbs produced by multiple techniques, and the results of clinical trials for anti-rabies mAbs cocktails recognizing non-overlapping epitopes are also discussed.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing ; Antibodies, Viral/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Horses ; Neutralization Tests ; Post-Exposure Prophylaxis/methods ; Rabies/prevention & control ; Rabies Vaccines ; Rabies virus
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Neutralizing ; Antibodies, Viral ; Antineoplastic Agents, Immunological ; Rabies Vaccines
    Language English
    Publishing date 2022-02-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.1080/21645515.2022.2026713
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top